SSWM
ALXN

Sheets Smith Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Sheets Smith Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,093
Closed -$855K – 336
2017
Q3 		$855K Buy
+6,093
New +$828K 0.22% 129
2015
Q1 		– Sell
-5,806
Closed -$1.07M – 265
2014
Q4 		$1.07M Buy
+5,806
New +$1.08M 0.28% 104

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sheets Smith Wealth Management's ALXN Position: Q4 2017 in Review

Sheets Smith Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 6,093 shares — an estimated $855K sold.

Sheets Smith Wealth Management first reported a position in ALXN in Q4 2014 and held it in 2 quarters. The position peaked at $1.07M in Q4 2014. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Sheets Smith Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Sheets Smith Wealth Management sold 6,093 Alexion Pharmaceuticals shares in Q4 2017, an estimated $855K.
  • Sheets Smith Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Sheets Smith Wealth Management's Alexion Pharmaceuticals position peaked at $1.07M in Q4 2014.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Sheets Smith Wealth Management's 13F filing for Q4 2017, filed 12 Jan 2018.